HYPOTHETICAL PATIENT PROFILES: HENRY, PATRICIA, AND STANLEY

The following are hypothetical patient profiles. All images and photographs are representative and are not of actual IMLYGIC® patients.

This section is intended to help you determine the types of patients who may be appropriate for treatment with IMLYGIC®.1

Photograph of a hypothetical patient with Stage IIIB melanoma

Henry

A 60-year-old Caucasian patient with unresectable in-transit recurrence (Stage IIIB)1

  • Married, 3 children
  • Full-time operator of a hardware store
Photograph of a hypothetical patient with Stage IIIC melanoma

Patricia

A 37-year-old Caucasian patient with unresectable nodal recurrence (Stage IIIC)1,3

  • Single, 2 young children
  • High school substitute teacher
Photograph of a hypothetical patient with Stage IVM1a melanoma

Stanley

A 67-year-old Caucasian patient with mixed response to systemic immunotherapy (Stage IVM1a)1

  • Widower, 7 grandchildren

Lesion Tracking Sheet

The Lesion Tracking Sheet can help you document treatment of melanoma lesions.

Download now

REVIEW INFORMATION ABOUT THE EFFICACY OF IMLYGIC®

See the data

REFERENCES

  1. IMLYGIC® (talimogene laherparepvec) Prescribing Information, BioVex, Inc., a subsidiary of Amgen Inc.
  2. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
  3. American Cancer Society. Melanoma Skin Cancer. http://
    www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdf.pdf. Accessed January 10, 2017.